Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics (NRIX) reported Q1 2025 financial results and corporate updates. The company's lead BTK degrader NX-5948 received the nonproprietary name 'bexobrutideg' and FDA Orphan Drug Designation for Waldenström macroglobulinemia. Revenue increased to $18.5M from $16.6M year-over-year, including $7M in Sanofi collaboration milestones.
The company achieved significant milestones, including a $15M license extension fee from Sanofi and strengthened its leadership with Roy D. Baynes joining the board and John Northcott as chief commercial officer. R&D expenses rose to $69.7M from $50.0M, while G&A expenses slightly decreased to $11.7M.
The company reported a net loss of $56.4M ($0.67 per share) compared to $41.5M ($0.76 per share) in the previous year. Nurix maintains a strong financial position with $549.7M in cash and marketable securities, excluding recent milestone payments.
Nurix Therapeutics (NRIX) ha riportato i risultati finanziari del primo trimestre 2025 e aggiornamenti aziendali. Il principale degrader BTK dell'azienda, NX-5948, ha ricevuto il nome non proprietario 'bexobrutideg' e la Designazione di Farmaco Orfano da parte della FDA per la macroglobulinemia di Waldenström. Il fatturato è aumentato a 18,5 milioni di dollari rispetto ai 16,6 milioni dell'anno precedente, inclusi 7 milioni di dollari in traguardi di collaborazione con Sanofi.
L'azienda ha raggiunto traguardi significativi, tra cui una tassa di estensione della licenza di 15 milioni di dollari da Sanofi e ha rafforzato la sua leadership con l'ingresso di Roy D. Baynes nel consiglio e John Northcott come direttore commerciale. Le spese per R&S sono aumentate a 69,7 milioni di dollari rispetto ai 50,0 milioni, mentre le spese generali e amministrative sono leggermente diminuite a 11,7 milioni.
L'azienda ha riportato una perdita netta di 56,4 milioni di dollari (0,67 dollari per azione) rispetto ai 41,5 milioni di dollari (0,76 dollari per azione) dell'anno precedente. Nurix mantiene una solida posizione finanziaria con 549,7 milioni di dollari in contanti e titoli negoziabili, escludendo i recenti pagamenti per traguardi.
Nurix Therapeutics (NRIX) informó sobre los resultados financieros del primer trimestre de 2025 y actualizaciones corporativas. El principal degradador de BTK de la compañía, NX-5948, recibió el nombre no propietario 'bexobrutideg' y la Designación de Medicamento Huérfano de la FDA para la macroglobulinemia de Waldenström. Los ingresos aumentaron a 18,5 millones de dólares desde 16,6 millones del año anterior, incluyendo 7 millones en hitos de colaboración con Sanofi.
La compañía logró hitos significativos, incluyendo una tarifa de extensión de licencia de 15 millones de dólares de Sanofi y fortaleció su liderazgo con la incorporación de Roy D. Baynes a la junta y John Northcott como director comercial. Los gastos de I+D aumentaron a 69,7 millones de dólares desde 50,0 millones, mientras que los gastos generales y administrativos disminuyeron ligeramente a 11,7 millones.
La compañía reportó una pérdida neta de 56,4 millones de dólares (0,67 dólares por acción) en comparación con 41,5 millones de dólares (0,76 dólares por acción) del año anterior. Nurix mantiene una sólida posición financiera con 549,7 millones de dólares en efectivo y valores negociables, excluyendo los recientes pagos por hitos.
Nurix Therapeutics (NRIX)는 2025년 1분기 재무 결과 및 기업 업데이트를 보고했습니다. 회사의 주요 BTK 분해제인 NX-5948은 비독점 이름 'bexobrutideg'를 받았으며, 월든스트롬 거대단백혈증에 대한 FDA의 희귀의약품 지정도 받았습니다. 수익은 1,850만 달러로 증가했습니다, 전년 대비 1,660만 달러에서 증가했으며, 여기에는 사노피와의 협력 이정표에서 700만 달러가 포함됩니다.
회사는 사노피로부터 1,500만 달러의 라이센스 연장 수수료를 포함하여 중요한 이정표를 달성했으며, 로이 D. 베인스가 이사회의 일원이 되고 존 노스콧이 최고 상업 책임자로 합류하면서 리더십을 강화했습니다. 연구개발 비용은 6,970만 달러로 증가했습니다 (5,000만 달러에서 증가), 반면 일반 관리 비용은 소폭 감소하여 1,170만 달러가 되었습니다.
회사는 5,640만 달러의 순손실을 보고했습니다 (주당 0.67달러), 전년의 4,150만 달러 (주당 0.76달러)와 비교됩니다. Nurix는 최근의 이정표 지급을 제외하고 5억 4,970만 달러의 현금 및 유가증권을 보유하여 강력한 재무 상태를 유지하고 있습니다.
Nurix Therapeutics (NRIX) a rapporté les résultats financiers du premier trimestre 2025 et des mises à jour d'entreprise. Le principal dégradant BTK de l'entreprise, NX-5948, a reçu le nom non protégé 'bexobrutideg' et la désignation de médicament orphelin par la FDA pour la macroglobulinémie de Waldenström. Les revenus ont augmenté à 18,5 millions de dollars contre 16,6 millions de dollars l'année précédente, y compris 7 millions de dollars en jalons de collaboration avec Sanofi.
L'entreprise a atteint des jalons significatifs, y compris des frais de prolongation de licence de 15 millions de dollars de Sanofi, et a renforcé sa direction avec l'entrée de Roy D. Baynes au conseil d'administration et John Northcott comme directeur commercial. Les dépenses de R&D ont augmenté à 69,7 millions de dollars contre 50,0 millions de dollars, tandis que les dépenses générales et administratives ont légèrement diminué à 11,7 millions de dollars.
L'entreprise a rapporté une perte nette de 56,4 millions de dollars (0,67 dollar par action) par rapport à 41,5 millions de dollars (0,76 dollar par action) l'année précédente. Nurix maintient une solide position financière avec 549,7 millions de dollars en espèces et titres négociables, excluant les paiements récents pour jalons.
Nurix Therapeutics (NRIX) hat die finanziellen Ergebnisse für das erste Quartal 2025 und Unternehmensupdates veröffentlicht. Der führende BTK-Degrader des Unternehmens, NX-5948, erhielt den nicht geschützten Namen 'bexobrutideg' und die FDA Orphan Drug Designation für die Waldenström-Makroglobulinämie. Der Umsatz stieg auf 18,5 Millionen Dollar im Vergleich zu 16,6 Millionen Dollar im Vorjahr, einschließlich 7 Millionen Dollar aus Meilensteinen der Zusammenarbeit mit Sanofi.
Das Unternehmen erreichte bedeutende Meilensteine, darunter eine Lizenzverlängerungsgebühr von 15 Millionen Dollar von Sanofi, und stärkte seine Führung, indem Roy D. Baynes in den Vorstand eintrat und John Northcott als Chief Commercial Officer eingestellt wurde. Die F&E-Ausgaben stiegen auf 69,7 Millionen Dollar gegenüber 50,0 Millionen Dollar, während die allgemeinen und administrativen Ausgaben leicht auf 11,7 Millionen Dollar sanken.
Das Unternehmen berichtete von einem Nettoverlust von 56,4 Millionen Dollar (0,67 Dollar pro Aktie) im Vergleich zu 41,5 Millionen Dollar (0,76 Dollar pro Aktie) im Vorjahr. Nurix hält eine starke finanzielle Position mit 549,7 Millionen Dollar in Bargeld und handelbaren Wertpapieren, ohne die kürzlichen Meilensteinzahlungen zu berücksichtigen.
- Received FDA Orphan Drug Designation for bexobrutideg
- Achieved $22M in combined milestone and license payments from Sanofi
- Strong cash position of $549.7M
- Revenue increased 11.4% year-over-year to $18.5M
- Expanded pipeline with new drug development programs
- Net loss widened to $56.4M from $41.5M year-over-year
- R&D expenses increased 39.4% to $69.7M
- Cash position decreased from $609.6M to $549.7M quarter-over-quarter
Insights
Nurix's Q1 2025 results reveal mixed financial performance with some important regulatory and collaboration milestones. The company achieved
The key highlight is bexobrutideg (formerly NX-5948) receiving FDA Orphan Drug Designation for Waldenström macroglobulinemia, providing potential tax credits and seven years of market exclusivity upon approval. This designation strengthens the company's BTK degrader platform and validates their development approach. The creation of the "deg" suffix for protein degraders further differentiates this therapeutic class from traditional inhibitors.
With
Nurix is positioning for transition from purely clinical-stage to commercial-ready through strategic pipeline advancement and leadership enhancements, with the promising bexobrutideg program as the near-term focus.
Nurix's Q1 update reveals significant progress for their protein degradation platform, especially with their lead candidate bexobrutideg. The official naming with the "deg" suffix represents an important industry recognition of protein degraders as a distinct therapeutic class from conventional inhibitors - marking a paradigm shift in how these novel agents are categorized.
The FDA Orphan Drug Designation for Waldenström macroglobulinemia strategically positions bexobrutideg in a specialized indication with treatment options. Beyond the regulatory advantages, this designation validates the clinical potential of their BTK degradation approach in rare B-cell malignancies. The planned expansion into autoimmune indications with bexobrutideg demonstrates the platform's versatility beyond oncology.
The pipeline demonstrates comprehensive development with four distinct clinical-stage candidates targeting different mechanisms: bexobrutideg (brain-penetrant BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), NX-1607 (CBL-B inhibitor), and partner-led GS-6791 (IRAK4 degrader). The portfolio shows sophisticated target selection across multiple therapeutic areas including oncology, immunology, and inflammation.
The increased R&D investment reflects appropriate acceleration of bexobrutideg's development toward pivotal trials. Nurix's strategic collaborations with Sanofi, Gilead and Pfizer provide external validation while defraying development costs and expanding target reach. With these partnerships and strong pipeline progression, Nurix is effectively positioning itself as a leading player in the targeted protein degradation field.
NX-5948 assigned the nonproprietary name “bexobrutideg”
U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia
Achieved
Enhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officer
Well capitalized with cash and marketable securities of
SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for the fiscal quarter ended February 28, 2025, and provided a corporate update.
“Nurix had a strong first quarter marked by important collaboration and regulatory achievements and key additions to our leadership team and Board,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Nurix remains on track to initiate pivotal trials of bexobrutideg, our oral, brain-penetrant, BTK degrader for the treatment of patients with chronic lymphocytic leukemia in 2025. In addition, Nurix continues to make significant progress with our pipeline of degrader-based drugs for the treatment of autoimmune disease and inflammation. Most recently we announced that Sanofi exercised its option to exclusively license an undisclosed Nurix program targeting a previously undruggable transcription factor that is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program.”
Recent Business Highlights
- Bexobrutideg is the new nonproprietary name for NX-5948: In March 2025, in collaboration with the national naming authority, the United States Adopted Name (USAN) Council, Nurix’s lead Bruton’s tyrosine kinase (BTK) degrader, NX-5948, was assigned the nonproprietary name “bexobrutideg.” The U.S. and international drug naming convention is designed to select a single name of worldwide acceptability for each active substance that is intended to be marketed as a pharmaceutical. Most notable with bexobrutideg is the designation of a new suffix, “deg,” which references bexobrutideg’s novel degradation mode of action. Targeted protein degraders are characterized by their bifunctional nature, binding to both a target protein and a ligase to drive ubiquitination and catalytic degradation of the target through the proteasome. The new deg suffix is an important recognition that the mechanism of action, pharmacokinetics and pharmacodynamics of targeted protein degraders are fundamentally different than inhibitors, which all use the “ib” suffix. The central stem of the name, “bruti,” references the target, Bruton’s tyrosine kinase (as used in ibrutinib, zanubrutinib and acalabrutinib), and the prefix “bexo” is the unique identifier of a specific agent in the class and is often used for ease of reference to the agent.
- Bexobrutideg received U.S. FDA Orphan Drug designation for Waldenström macroglobulinemia: In March 2025, bexobrutideg was granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of Waldenström macroglobulinemia (WM). The FDA's Orphan Drug Designation program provides orphan status to therapies intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. This designation provides certain benefits, including tax credits for qualified clinical testing, waiver or partial payment of FDA application fees and seven years of market exclusivity, if approved.
- Announced the appointment of Roy Baynes to Nurix’s board of directors: In March 2025, Nurix announced the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes currently serves as executive vice president and chief medical officer of Eikon Therapeutics and has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. Dr. Baynes previously served as chief medical officer and head of global clinical development at Merck, where he supervised the entire clinical portfolio at Merck Research Laboratories. Earlier in his career, Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit, where he held the Charles Martin endowed chair of Cancer Research.
- Announced the appointment of John Northcott as chief commercial officer: In January 2025, Nurix announced the appointment of John Northcott as chief commercial officer. Mr. Northcott joins the executive team as Nurix prepares to launch its pivotal clinical program for NX-5948 in chronic lymphocytic leukemia (CLL) and potentially other B-cell malignancies. Mr. Northcott has extensive U.S. and global commercial leadership experience including the successful commercialization of the first marketed BTK inhibitor ibrutinib, and in a wide range of other therapeutic areas.
Upcoming Program Highlights*
Bexobrutideg (NX-5948): Bexobrutideg is an investigational, orally bioavailable, brain-penetrant, small molecule degrader of BTK. Nurix currently is conducting a Phase 1b clinical trial of bexobrutideg in adults with relapsed or refractory B-cell malignancies. In 2025, Nurix plans to commence a suite of clinical trials designed to support global registration of bexobrutideg for the treatment of patients with CLL. In addition, Nurix anticipates moving into autoimmune and inflammatory diseases and expects to open a new Phase 1b cohort for patients with CLL and associated autoimmune hemolytic anemia and is exploring the filing of a non-malignant hematology IND for autoimmune cytopenias in 2025. Future clinical updates in patients with both CLL and non-Hodgkin’s lymphoma are anticipated in 2025. Additional information on the NX-5948 clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022).
NX-2127: NX-2127 is an orally bioavailable degrader of BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. Nurix currently is conducting a Phase 1a/b clinical trial of NX-2127, which includes Phase 1b expansion cohorts focused on patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Following a decision in March 2024 in which the FDA lifted a manufacturing-related, partial clinical hold on the NX-2127 clinical trial, Nurix reinitiated enrollment in a dose escalation study within the current Phase 1a/1b trial using its new chirally controlled drug product. Future clinical updates are anticipated in 2025. Additional information on the NX-2127 clinical trial can be accessed at www.clinicaltrials.gov (NCT04830137).
NX-1607: NX-1607 is an orally bioavailable inhibitor of the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) for immuno-oncology indications, including a range of solid tumor types and lymphoma. Nurix currently is evaluating NX-1607 in an ongoing Phase 1 trial in monotherapy and in a combination cohort utilizing paclitaxel in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in Phase 1a. Future clinical updates are anticipated in 2025. Additional information on the NX-1607 clinical trial can be accessed at www.clinicaltrials.gov (NCT05107674).
GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral degrader of IRAK4. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix’s partner, Gilead, is responsible for conducting IND-enabling studies and advancing this program to clinical development, which Nurix anticipates in 2025.
STAT6 degrader: In April 2024, Nurix announced an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6), a key drug target in type 2 inflammation, with the goal of nominating a development candidate in the first year of the extended term.
Continued pipeline advancement of strategic collaborations with Gilead, Sanofi and Pfizer: Nurix expects to continue to achieve substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi and Pfizer.
* Expected timing of events throughout this press release is based on calendar year quarters.
Fiscal First Quarter 2025 Financial Results
Revenue for the three months ended February 28, 2025, was
Research and development expenses for three months ended February 28, 2025, were
General and administrative expenses for the three months ended February 28, 2025, were
Net loss for the three months ended February 28, 2025, was
Cash, cash equivalents and marketable securities was
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s future financial or business performance; Nurix’s future plans, prospects and strategies; Nurix’s plans and expectations with respect to its current and prospective drug candidates; the tolerability, safety profile, therapeutic potential and other advantages of Nurix’s drug candidates; the planned timing and conduct of Nurix’s clinical trials; the planned timing for the provision of updates and findings from Nurix’s preclinical studies and clinical trials; the potential benefits of and Nurix’s expectations with respect to its strategic collaborations, including the achievement of research milestones; and the potential benefits and advantages of Nurix’s scientific approach, DEL-AI platform and degrader antibody conjugates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, its future plans and strategies, its development plans, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix will be able to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) uncertainties related to the timing and results of preclinical studies and clinical trials; (iii) whether Nurix will be able to fund development activities and achieve development goals; (iv) uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future product sales; (v) the impact of global business, political and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events, including regional conflicts around the world, on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (vi) whether Nurix will be able to protect intellectual property and (vii) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended February 28, 2025, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
| Nurix Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share amounts) (unaudited) | |||||||
| Three Months Ended | |||||||
| February 28, 2025 | February 29, 2024 | ||||||
| Revenue: | |||||||
| Collaboration revenue | $ | 18,453 | $ | 16,585 | |||
| Total revenue | 18,453 | 16,585 | |||||
| Operating expenses: | |||||||
| Research and development | 69,663 | 50,005 | |||||
| General and administrative | 11,654 | 11,799 | |||||
| Total operating expenses | 81,317 | 61,804 | |||||
| Loss from operations | (62,864 | ) | (45,219 | ) | |||
| Interest and other income, net | 6,513 | 3,791 | |||||
| Loss before income taxes | (56,351 | ) | (41,428 | ) | |||
| Provision for income taxes | — | 90 | |||||
| Net loss | (56,351 | ) | (41,518 | ) | |||
| Net loss per share, basic and diluted | $ | (0.67 | ) | $ | (0.76 | ) | |
| Weighted-average number of shares outstanding, basic and diluted | 83,560,795 | 54,903,407 | |||||
| Nurix Therapeutics, Inc. Condensed Balance Sheets (in thousands) (unaudited) | |||||||
| February 28, 2025 | November 30, 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 75,916 | $ | 109,997 | |||
| Marketable securities, current | 473,764 | 499,586 | |||||
| Prepaid expenses and other current assets | 14,023 | 9,804 | |||||
| Total current assets | 563,703 | 619,387 | |||||
| Operating lease right-of-use assets | 26,361 | 28,139 | |||||
| Property and equipment, net | 18,449 | 17,757 | |||||
| Restricted cash | 901 | 901 | |||||
| Other assets | 5,629 | 3,159 | |||||
| Total assets | $ | 615,043 | $ | 669,343 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 8,397 | $ | 11,482 | |||
| Accrued expenses and other current liabilities | 44,361 | 37,994 | |||||
| Operating lease liabilities, current | 6,639 | 8,014 | |||||
| Deferred revenue, current | 30,591 | 38,364 | |||||
| Total current liabilities | 89,988 | 95,854 | |||||
| Operating lease liabilities, net of current portion | 19,984 | 20,289 | |||||
| Deferred revenue, net of current portion | 24,154 | 26,207 | |||||
| Total liabilities | 134,126 | 142,350 | |||||
| Stockholders’ equity: | |||||||
| Common stock | 76 | 76 | |||||
| Additional paid-in-capital | 1,275,735 | 1,265,536 | |||||
| Accumulated other comprehensive income | 226 | 150 | |||||
| Accumulated deficit | (795,120 | ) | (738,769 | ) | |||
| Total stockholders’ equity | 480,917 | 526,993 | |||||
| Total liabilities and stockholders’ equity | $ | 615,043 | $ | 669,343 | |||
FAQ
What is the significance of bexobrutideg's Orphan Drug Designation for NRIX?
How much revenue did NRIX generate in Q1 2025?
What is NRIX's current cash position as of Q1 2025?
What are the key clinical developments planned for bexobrutideg in 2025?
How did NRIX's R&D expenses change in Q1 2025?
